thalidomide has been researched along with transforming growth factor beta in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Flockhart, DA; Greenlee, BM; Karp, CL; Ma, X; Moller, DR; Trinchieri, G; Wahl, L; Wysocka, M | 1 |
| Allampallam, K; Dar, S; Dutt, D; Gezer, S; Lisak, L; Nascimben, F; Raza, A; Shetty, V; Venugopal, P; York, A; Zorat, F | 1 |
| Pozzato, G; Zorat, F | 1 |
| Chen, MF; Ho, YP; Huang, SF; Jan, YY; Yeh, JN; Yeh, TS | 1 |
| Hunt, BJ; Jones, R; Parmar, K; Schey, S; Streetly, M; Zeldis, J | 1 |
| Haruta, S; Inagaki, K; Kanayama, N; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Kondo, T; Kurita, N; Sakamoto, Y; Terao, T; Yagyu, T; Yamada, Y | 1 |
| Chiu, YT; Chong, LW; Hsu, YC; Huang, YT; Yang, KC | 1 |
| Crisafulli, C; Cuzzocrea, S; Di Paola, R; Genovese, T; Malleo, G; Mazzon, E; Muià, C; Siriwardena, AK | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Bartlett, JB; Chen, R; Dalgleish, AG; Dredge, K; Galustian, C; Henry, J; Klaschka, D; Labarthe, MC; Meyer, B; Muller, G; Schafer, P; Stirling, D; Todryk, S | 1 |
| Aloisi, C; Buemi, M; Crisafulli, C; Cuzzocrea, S; Di Paola, R; Mazzon, E; Mondello, P; Mondello, S | 1 |
| Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S | 1 |
| Alexandrescu, S; Brown, RE; Burns, NK; Covinsky, MH; Czerniak, BA; Tatevian, N | 1 |
| List, AF | 1 |
| Han, W; Liu, J; Wang, S; Wang, X; Yan, Q; Yang, X | 1 |
| Balaian, E; Bornhäuser, M; Ehninger, G; Germing, U; Haase, D; Mohr, B; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Schönefeldt, C; Schuster, C; Tuve, S; von Bonin, M; Wermke, M | 1 |
| Giagounidis, A | 1 |
| Bian, C; Chen, J; Qin, WJ; Wang, YY; Zhang, CY; Zhao, R; Zhe, H; Zhu, YZ; Zou, GL | 1 |
| Marafini, I; Monteleone, G; Salvatori, S; Troncone, E | 1 |
| Fan, LJ; Jiang, P; Li, XG; Lv, P; Meng, QS; Zhang, J; Zhao, ZH | 1 |
| Alampady, V; Baby, K; Byregowda, BH; Dsouza, NN; Maity, S; Nayak, Y | 1 |
| Guo, R; He, J; Hou, M; Jiang, JH; Ren, T; Wang, T | 1 |
6 review(s) available for thalidomide and transforming growth factor beta
| Article | Year |
|---|---|
Thalidomide in myelodysplastic syndromes.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Aberrations; Constipation; Cytokines; Dyspnea; Fatigue; Humans; Immunosuppressive Agents; Interleukin-1; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Thalidomide; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2002 |
[Pathophysiology of and therapy for primary myelofibrosis].
Topics: Animals; Cytokines; Hematopoietic Stem Cell Transplantation; Humans; Janus Kinase 2; Mutation; Primary Myelofibrosis; Signal Transduction; Thalidomide; Transforming Growth Factor beta; Transplantation, Homologous | 2007 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydroxamic Acids; Lenalidomide; Myelodysplastic Syndromes; Neoplastic Stem Cells; p38 Mitogen-Activated Protein Kinases; Sequence Deletion; Sulfones; Thalidomide; Transforming Growth Factor beta; Tumor Microenvironment | 2012 |
Current treatment algorithm for the management of lower-risk MDS.
Topics: Algorithms; Allografts; Erythrocyte Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transforming Growth Factor beta | 2017 |
TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Oligonucleotides; Phosphodiesterase 4 Inhibitors; Thalidomide; Thiazoles; Transforming Growth Factor beta | 2020 |
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.
Topics: COVID-19; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Lung; Pandemics; Thalidomide; Transforming Growth Factor beta | 2023 |
2 trial(s) available for thalidomide and transforming growth factor beta
| Article | Year |
|---|---|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome | 2009 |
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Topics: Aged; Aged, 80 and over; Anemia, Macrocytic; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2016 |
15 other study(ies) available for thalidomide and transforming growth factor beta
| Article | Year |
|---|---|
Inhibition of IL-12 production by thalidomide.
Topics: Antibodies, Monoclonal; Cells, Cultured; Humans; Immunosuppressive Agents; Indomethacin; Interleukin-10; Interleukin-12; Leukocytes, Mononuclear; Lymphocyte Activation; Monocytes; RNA, Messenger; Thalidomide; Transforming Growth Factor beta | 1997 |
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.
Topics: Aged; Case-Control Studies; Cytokines; Endothelial Growth Factors; Female; Hemoglobins; Humans; Immunosuppressive Agents; Lymphokines; Male; Myelodysplastic Syndromes; Platelet Count; Remission Induction; Thalidomide; Transforming Growth Factor alpha; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats.
Topics: Animals; Collagenases; Hepatitis; Kupffer Cells; Liver; Liver Cirrhosis, Experimental; Male; Matrix Metalloproteinase 13; Necrosis; Rats; Rats, Sprague-Dawley; Salvage Therapy; Thalidomide; Time Factors; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2004 |
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Humans; Immunologic Factors; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transforming Growth Factor beta; Transforming Growth Factor beta2; Vascular Endothelial Growth Factor A; Venous Thrombosis | 2005 |
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chondrosarcoma; Drug Synergism; Female; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Thalidomide; Transforming Growth Factor beta; Transforming Growth Factor beta1; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2005 |
Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats.
Topics: Actins; Animals; Collagen; Dimethylnitrosamine; Fibrosis; I-kappa B Proteins; Immunosuppressive Agents; Liver; Liver Cirrhosis, Experimental; Muscle, Smooth; NF-kappa B; NF-KappaB Inhibitor alpha; Rats; Thalidomide; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2006 |
Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis.
Topics: Animals; Apoptosis; Ceruletide; Disease Models, Animal; Immunologic Factors; Intercellular Adhesion Molecule-1; Interleukin-1beta; Male; Mice; Neutrophils; P-Selectin; Pancreatitis, Acute Necrotizing; Thalidomide; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Female; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunosuppressive Agents; Interleukin-10; Lenalidomide; Mice; Mice, Inbred BALB C; Receptors, Nerve Growth Factor; Receptors, OX40; Receptors, Transforming Growth Factor beta; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2009 |
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model.
Topics: Animals; Anti-Infective Agents; Blotting, Western; Chlorhexidine; Disease Models, Animal; Enzyme Activation; Gene Expression Regulation; I-kappa B Proteins; Immunohistochemistry; Immunosuppressive Agents; NF-kappa B; Nitric Oxide Synthase Type II; Peritonitis; Peroxidase; Poly Adenosine Diphosphate Ribose; Rats; Thalidomide; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Tyrosine; Vascular Endothelial Growth Factor A | 2009 |
Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.
Topics: Biomarkers; Cell Differentiation; Cell Membrane; Cell Nucleus; Child; Child, Preschool; Cytoplasm; Female; Histiocytosis, Langerhans-Cell; Humans; Kruppel-Like Transcription Factors; Male; Nuclear Proteins; Osteoclasts; Osteolysis; Proteomics; Signal Transduction; Thalidomide; Transforming Growth Factor beta; Zinc Finger Protein Gli2 | 2012 |
Investigating the role of angiogenesis in systemic lupus erythematosus.
Topics: Adult; Angiogenesis Inhibitors; Autoantibodies; Biomarkers; Endostatins; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Thalidomide; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner.
Topics: A549 Cells; Animals; Cell Line, Tumor; Epithelial Cells; Female; Gene Expression Regulation; Humans; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiation-Protective Agents; Reactive Oxygen Species; Signal Transduction; Smad3 Protein; Thalidomide; THP-1 Cells; Transforming Growth Factor beta; X-Rays | 2018 |
Thalidomide Reduces Activation of Murine Pancreatic Stellate Cells by Inhibiting the TGF-β/Smad Pathway.
Topics: Actins; Angiogenesis Inhibitors; Animals; Collagen Type I; Male; Mice; Mice, Inbred C57BL; Pancreatic Stellate Cells; Signal Transduction; Smad3 Protein; Smad7 Protein; Thalidomide; Transforming Growth Factor beta | 2021 |
Selective Proteolysis of Activated Transcriptional Factor by NIR-Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway.
Topics: DNA; Gene Expression Regulation; Proteolysis; Thalidomide; Transcription Factors; Transforming Growth Factor beta | 2023 |